Chemo Regimen for Ovarian Cancer Concord NC

Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients in Concord, according to the new study findings.

Cameron Trent Blackman, MD
(704) 786-5131
200 Medical Park Dr Ste 280
Concord, NC
Specialties
Urology
Gender
Male
Languages
English
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1988
Hospital
Hospital: Northeast Med Ctr, Concord, Nc
Group Practice: Cabarrus Urology Clinic

Data Provided by:
David Uri Lipsitz, MD
(704) 786-5131
200 Medical Park Dr Ste 280
Concord, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Co Sch Of Med, Denver Co 80262
Graduation Year: 1990

Data Provided by:
David Uri Lipsitz
(704) 786-5131
1084 Vinehaven Dr
Concord, NC
Specialty
Urology

Data Provided by:
Joseph Michael DeBord
(704) 786-5131
1084 Vinehaven Dr
Concord, NC
Specialty
Urology

Data Provided by:
John Mclean Nordan
(704) 786-5131
1084 Vinehaven Dr
Concord, NC
Specialty
Urology

Data Provided by:
John Mc Lean Nordan, MD
(704) 786-5131
200 Medical Park Dr Ste 280
Concord, NC
Specialties
Urology
Gender
Male
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1969
Hospital
Hospital: Northeast Med Ctr, Concord, Nc
Group Practice: Cabarrus Urology Clinic

Data Provided by:
S Stuart Du Puy Jr, MD
(704) 375-5755
200 Medical Park Dr Ste 280
Concord, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Fl Coll Of Med, Gainesville Fl 32610
Graduation Year: 1969
Hospital
Hospital: Carolinas Med Ctr, Charlotte, Nc; Presbyterian Hospital, Charlotte, Nc

Data Provided by:
Joseph Michael Debord, MD
(704) 786-5131
200 Medical Park Dr Ste 280
Concord, NC
Specialties
Urology
Gender
Male
Education
Medical School: Wv Univ Sch Of Med, Morgantown Wv 26506
Graduation Year: 1990

Data Provided by:
Cameron Trent Blackman
(704) 786-5134
1084 Vinehaven Dr
Concord, NC
Specialty
Urology

Data Provided by:
Harrison Kuhn Rhee
(704) 707-2200
1085 Ne Gateway Ct
Concord, NC
Specialty
Urology

Data Provided by:
Data Provided by:

Chemo Regimen for Ovarian Cancer

Provided By:

SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say.

Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings.

This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous infusion) on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

The patients in the dose-dense group had longer median progression-free survival than those in the standard treatment group (28 months versus 17 months), and longer overall survival at three years (72 percent versus 65 percent). This means that women in the dose-dense group had a 29 percent lower risk of cancer progression and a 25 percent lower risk of death, the authors explained.

Toxicity forced 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment, the researchers noted. Severe anemia occurred in 214 patients (69 percent) in the dose-dense group and in 137 (44 percent) of the standard therapy group.

The survival benefits seen in the dose-dense group are rare in patients with advanced ovarian cancer, and this regimen offers a new treatment option for women with advanced epithelial ovarian cancer, concluded Dr. Noriyuki Katsumata, of the National Cancer Center Hospital in Tokyo, and colleagues.

The study, published in an upcoming print issue of The Lancet, was released online Sunday to coincide with the European Cancer Organization meeting held Sept. 20 to 24 in Berlin.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer," Dr. Michael A. Bookman, of the Arizona Cancer Center in Tucson, wrote in an accompanying commentary in The Lancet.

More information

The U.S. National Cancer Institute has more about ovarian cancer.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com